OncLive TV

Dr. Salem on the Utility of Y-90 Glass Microspheres in CRC

August 23rd 2021

Riad Salem, MD, discusses the history of TheraSphere™ Yttrium-90 in metastatic colorectal cancer.

Dr. Hammers on the Safety Profile of Lenvatinib/Pembrolizumab in RCC

August 20th 2021

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

August 20th 2021

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Dr. Vose on the Potential Utility of CAR T-Cell Therapy Across Non-Hodgkin Lymphoma

August 20th 2021

Julie M. Vose, MD, MBA, discusses the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma paradigm.

Dr. Spicer on Outcomes from the CheckMate-816 Trial in NSCLC

August 20th 2021

Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.

Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

August 19th 2021

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Dr. Morris on Findings From the TheraP Study in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

August 19th 2021

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

August 19th 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Dr. Kumar on the Future Directions With Pirtobrutinib in MCL

August 19th 2021

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Dr. Abida on Data from the PROfound Study in mCRPC

August 19th 2021

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Dr. Scott on the Rationale to Evaluate GARD-Based Radiotherapy Dosing in Oncology

August 18th 2021

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Patel on the Potential Utility of Elranatamab in Multiple Myeloma

August 18th 2021

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Dr. Ansell on the Utility of Non–CAR T-Cell Therapies in Non-Hodgkin Lymphoma

August 18th 2021

Stephen M. Ansell, MD, PhD, discusses the utility of non–CAR T-cell therapy options in non-Hodgkin lymphoma.

Dr. Kumar on Addressing Unmet Needs in Mantle Cell Lymphoma

August 17th 2021

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Dr. Extermann on Selecting Among Available CDK4/6 Inhibitors in HR+ Breast Cancer

August 16th 2021

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 16th 2021

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Dr. Carey on the Updated Results of the PALOMA-3 Trial in HR+/HER2- Breast Cancer

August 16th 2021

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.